Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PSIP1 | O75475 | 2/20 | 0.48 |
| ▸ | RORC | P51449 | 6/20 | 0.42 |
| ▸ | RORA | P35398 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17688647 | 1.00 | GAA (0.50) | GAAPSIP1RORCRORACA2 | |
| SCHEMBL21570457 | 1.00 | GAA (0.50) | GAAPSIP1RORCRORACA2 | |
| Methyl Alcohol SCHEMBL29070040 | 0.98 | GAA (0.48) | GAAPSIP1RORCRORACA2 | |
| Hydrochloric Acid SCHEMBL18440748 | 0.98 | GAA (0.53) | GAAPSIP1RORCRORACA2 | |
| Methyl Alcohol SCHEMBL29070039 | 0.98 | GAA (0.48) | GAAPSIP1RORCRORACA2 | |
| Hydrochloric Acid SCHEMBL17711637 | 0.98 | GAA (0.53) | GAAPSIP1RORCRORACA2 | |
| SCHEMBL23632951 | 0.86 | GAA (0.47) | GAAPSIP1RORCRORACA2 | |
| SCHEMBL17711706 | 0.86 | GAA (0.47) | GAAPSIP1RORCRORACA2 | |
| SCHEMBL17711707 | 0.86 | GAA (0.47) | GAAPSIP1RORCRORACA2 | |
| SCHEMBL16232126 | 0.85 | GAA (0.53) | GAAPSIP1RORCRORACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072546-B | Five-membered heteroaromatic derivative and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-113072476-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-113302185-B | Benzofuran-6-carboxamide derivatives, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-113072521-B | ROR gamma t inhibitor and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-113072542-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117800904-A | ROR gamma inhibitors containing sulfonyl structures | 正大天晴药业集团股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-113166061-B | ROR gamma inhibitors containing sulfonyl structures | 正大天晴药业集团股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-112601745-B | Azaaryl amide derivative and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-112513021-B | ROR gamma antagonist and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-113912597-B | ROR gamma inhibitor, preparation method and medical application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2017024018-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-9481674-B1 | Dihydropyrrolopyridine inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160122345-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-05-05 | — | — | US | disclosed |
| US-20160122318-A1 | ISOINDOLINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-05-05 | — | — | US | disclosed |
| US-20160122318-A1 | ISOINDOLINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-05-05 | — | — | US | disclosed |
| US-20160122345-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-05-05 | — | — | US | disclosed |
| US-20160122345-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-05-05 | — | — | US | disclosed |
| US-20160122318-A1 | ISOINDOLINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-05-05 | — | — | US | disclosed |
| WO-2016061160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2016061160-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122318-A1 | ISOINDOLINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | GAA 1078/4885PSIP1 2830/4885RORC 1/4885 |
| US-20160122345-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | GAA 594/4885PSIP1 2094/4885RORC 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.